GenSpera plans to initiate G-202 Phase II trial in prostate cancer

GenSpera, Inc. (OTCBB:GNSZ) announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy. The Phase II study, which was approved by the United States (US) Food and Drug Administration in July 2012, will be conducted at up to six sites in the US and the UK and will enroll up to 40 patients with chemotherapy-naïve, metastatic castrate-resistant prostate cancer. GenSpera plans to initiate the UK study pending clearance from the Multicentre Research Ethics Committee (MREC).    

"This authorization for GenSpera's first clinical trial outside of the US is an important milestone for our company and underscores our commitment to an international clinical development program for G-202, in parallel with the US program," said Craig Dionne, PhD, GenSpera CEO and President."    


GenSpera, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
The role of bacteria in cancer growth